Published in:
Open Access
01-12-2012 | Poster presentation
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
Authors:
Byron Cryer, Chunming Li, Lee S Simon, Gurkirpal Singh, Martin J Stillman, Manuela Berger
Published in:
Arthritis Research & Therapy
|
Special Issue 1/2012
Login to get access
Excerpt
The GI Randomized Event and Safety Open-Label NSAID Study (GI-REASONS) was a novel prospective, randomized, open-label, blinded end point (PROBE) study that measured adjudicated clinical outcomes throughout the GI tract. It was designed to assess if celecoxib use in patients with osteoarthritis (OA) at moderate GI risk (≥55 y) is associated with a lower incidence of clinically significant upper and lower GI events compared to nsNSAIDs, with/without proton-pump inhibitors (PPIs), in standard US clinical practice. …